[go: up one dir, main page]

FR2892634B3 - Procedes de reduction du dose dumping induit par l'alcool pour des formes posologiques orales d'opioides a liberation prolongee - Google Patents

Procedes de reduction du dose dumping induit par l'alcool pour des formes posologiques orales d'opioides a liberation prolongee

Info

Publication number
FR2892634B3
FR2892634B3 FR0654649A FR0654649A FR2892634B3 FR 2892634 B3 FR2892634 B3 FR 2892634B3 FR 0654649 A FR0654649 A FR 0654649A FR 0654649 A FR0654649 A FR 0654649A FR 2892634 B3 FR2892634 B3 FR 2892634B3
Authority
FR
France
Prior art keywords
methods
forms
oral dosage
prolonged release
release opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0654649A
Other languages
English (en)
Other versions
FR2892634A3 (fr
Inventor
Gayatri Sathyan
Nipun Davar
Linda Hearney Pors
Gemma Casadevall
Jayne Hastedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37232345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2892634(B3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of FR2892634A3 publication Critical patent/FR2892634A3/fr
Application granted granted Critical
Publication of FR2892634B3 publication Critical patent/FR2892634B3/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR0654649A 2005-10-31 2006-10-31 Procedes de reduction du dose dumping induit par l'alcool pour des formes posologiques orales d'opioides a liberation prolongee Expired - Lifetime FR2892634B3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73199505P 2005-10-31 2005-10-31
US80201706P 2006-05-18 2006-05-18
US83704906P 2006-08-11 2006-08-11

Publications (2)

Publication Number Publication Date
FR2892634A3 FR2892634A3 (fr) 2007-05-04
FR2892634B3 true FR2892634B3 (fr) 2007-09-14

Family

ID=37232345

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0654649A Expired - Lifetime FR2892634B3 (fr) 2005-10-31 2006-10-31 Procedes de reduction du dose dumping induit par l'alcool pour des formes posologiques orales d'opioides a liberation prolongee

Country Status (23)

Country Link
US (1) US20090221621A1 (fr)
EP (1) EP1951232B1 (fr)
JP (1) JP5315055B2 (fr)
KR (1) KR101365031B1 (fr)
CN (1) CN103800300A (fr)
AT (1) AT10511U1 (fr)
AU (1) AU2006308718C8 (fr)
BE (1) BE1017786A3 (fr)
BG (1) BG1145U1 (fr)
CZ (1) CZ17801U1 (fr)
DE (1) DE202006014131U1 (fr)
DK (2) DK200600272U4 (fr)
ES (2) ES1064414Y (fr)
FI (1) FI7512U1 (fr)
FR (1) FR2892634B3 (fr)
HU (1) HUP0600816A2 (fr)
IE (1) IES20060793A2 (fr)
NL (1) NL1032774C1 (fr)
NO (2) NO20064997L (fr)
PL (2) PL116330U1 (fr)
PT (2) PT1951232E (fr)
SI (1) SI1951232T1 (fr)
WO (1) WO2007053698A2 (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004031A1 (fr) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Administration parenterale de 6-hydroxy-oxymorphone destinee a etre utilisee en tant qu'analgesique
EP2957281A1 (fr) 2001-09-21 2015-12-23 Egalet Ltd. Systeme de liberation a base de polymere
WO2003024430A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CN101188999B (zh) * 2005-06-03 2012-07-18 尹格莱特股份有限公司 用于递送分散在分散介质中的活性物质的药物传递系统
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de) * 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
PA8774201A1 (es) 2007-03-29 2009-06-23 Progenics Pharm Inc Antagonista del receptor
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
EP2155167A2 (fr) 2007-06-04 2010-02-24 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
KR20100136967A (ko) * 2008-02-15 2010-12-29 썬 파마 어드밴스트 리서치 컴패니 리미티드 파열 효과가 감소된 방출 제어 경구 정제
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
ES2620373T3 (es) 2008-07-01 2017-06-28 University Of Chicago Partículas que contienen un antagonista del receptor de opioides periférico
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
EP2393484A1 (fr) 2009-02-06 2011-12-14 Egalet Ltd. Composition à libération immédiate résistant à une maltraitance par prise d'alcool
DK2393487T3 (en) 2009-02-06 2017-01-23 Egalet Ltd Pharmaceutical compositions resistant to abuse
CA2755808C (fr) * 2009-03-18 2016-01-19 Evonik Roehm Gmbh Composition pharmaceutique a liberation controlee avec resistance contre l'influence de l'ethanol au moyen d'un enrobage comportant des polymeres vinyliques et excipients neutres
EP2445487A2 (fr) 2009-06-24 2012-05-02 Egalet Ltd. Formulations à libération contrôlée
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
JP2013504562A (ja) 2009-09-17 2013-02-07 カディラ・ヘルスケア・リミテッド アルコールで誘発される用量ダンピングを低減するための医薬組成物
BR112012020989A2 (pt) * 2010-02-24 2016-05-03 Pfizer composições veterinárias
ES2709766T3 (es) * 2010-03-09 2019-04-17 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas entéricas resistentes al alcohol
MX377251B (es) 2010-03-24 2025-03-07 Jazz Pharmaceuticals Inc Star Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
NO2736497T3 (fr) 2011-07-29 2018-01-20
CA2839123A1 (fr) 2011-07-29 2013-02-07 Grunenthal Gmbh Comprime anti-manipulation permettant une liberation immediate de medicament
WO2013127831A1 (fr) 2012-02-28 2013-09-06 Grünenthal GmbH Forme pharmaceutique inviolable comprenant un composé pharmacologiquement actif et un polymère anionique
MX356111B (es) 2012-04-18 2018-05-15 SpecGx LLC Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
RU2665372C2 (ru) * 2012-09-03 2018-08-29 Дайити Санкио Компани, Лимитед Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона
EP2968182B8 (fr) 2013-03-15 2018-07-25 SpecGx LLC Forme galénique solide dissuasive d'abus pour libération immédiate avec marque fonctionnelle
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
KR102385603B1 (ko) * 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
WO2015078891A1 (fr) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Préparation de composition pharmaceutique en poudre par cryo-broyage
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
PL3164117T3 (pl) 2014-07-03 2024-03-11 SpecGx LLC Preparaty zapewniające natychmiastowe uwalnianie i powstrzymujące przed nadużywaniem, zawierające polisacharydy inne niż celuloza
WO2016010771A1 (fr) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
CA2964628A1 (fr) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Forme galenique anti-abus de remplissage de liquide a liberation prolongee
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
AU2016259861B2 (en) * 2015-05-13 2020-08-13 4P-Pharma Stimulant abuse-deterrent compositions
EP3302444B1 (fr) * 2015-06-05 2020-09-23 Evonik Operations GmbH Composition pharmaceutique ou nutraceutique douée de résistance contre l'influence de l'éthanol
CA2998259A1 (fr) 2015-09-10 2017-03-16 Grunenthal Gmbh Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3856160A4 (fr) 2018-09-25 2022-07-06 SpecGx LLC Formes posologiques de capsules à libération immédiate anti-abus
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
JP7263047B2 (ja) * 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
WO2020178695A1 (fr) 2019-03-01 2020-09-10 Flamel Ireland Limited Compositions de gamma-hydroxybutyrate présentant une pharmacocinétique améliorée à l'état alimenté
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2707154A (en) * 1952-06-09 1955-04-26 Monsanto Chemicals Antioxidants and compositions containing same
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (fr) 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
CH508415A (de) * 1967-10-27 1971-06-15 Hoffmann La Roche Antioxydative Mischung und deren Verwendung
US3573936A (en) * 1967-12-15 1971-04-06 Rayonier Inc Plicatic acid and thiodipropionic acid as antioxidants for use in animal fats and vegetable oils
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4038434A (en) * 1976-03-12 1977-07-26 Howard Hall & Company Antioxidant stabilized edible compositions
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4186465A (en) 1978-03-28 1980-02-05 Manning Jim L Safety lock
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4259323A (en) * 1980-03-24 1981-03-31 Hoffmann-La Roche Inc. Potassium chloride emulsion
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
IN159370B (fr) 1982-01-15 1987-05-09 Ciba Geigy Ag
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4663148A (en) 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4681853A (en) * 1985-10-23 1987-07-21 Hardy Kenneth J Perfusion slit chamber for filter-bound sample analyses
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
CA1340821C (fr) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Composes heterocycliques, ainsi que des adjuvants de produits anti-cancereux les comprenant
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5091190A (en) 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
KR100333115B1 (ko) * 1992-11-17 2002-12-02 미츠비시 파마 코포레이션 항정신병약함유서방성마이크로스피어및이의제조방법
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
EP1442745A1 (fr) * 1993-10-07 2004-08-04 Euro-Celtique Compositions d'opioides pour administration orale ayant un effet prolongé
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
HU219487B (hu) 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
EP0729353B2 (fr) * 1993-11-19 2012-09-12 Alkermes, Inc. Preparation de microparticules biodegradables contenant un agent biologiquement actif
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1998006380A2 (fr) 1996-08-16 1998-02-19 Alza Corporation Forme galenique destinee a fournir une dose croissante de medicament
EP0946151B1 (fr) 1996-11-25 2006-05-10 Alza Corporation Forme posologique a doses croissantes
ES2263211T3 (es) * 1997-07-02 2006-12-01 Euro-Celtique S.A. Formulaciones de tramadol de liberacion sostenida estabilizada.
EP1041988A4 (fr) * 1997-12-22 2002-03-13 Euro Celtique Sa Procede prevenant l'abus des doses orales d'opioides
JP2002516848A (ja) 1998-06-03 2002-06-11 アルザ・コーポレーション 長時間の薬物療法を与える方法および装置
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
CN1161101C (zh) 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
NZ536252A (en) * 2002-04-29 2007-06-29 Alza Corp Methods and dosage forms for controlled delivery of oxycodone

Also Published As

Publication number Publication date
CZ17801U1 (cs) 2007-09-03
JP5315055B2 (ja) 2013-10-16
PL116330U1 (en) 2007-04-02
HK1115070A1 (en) 2008-11-21
ES1064414Y (es) 2007-06-16
HU0600816D0 (en) 2006-12-28
AT10511U1 (de) 2009-05-15
WO2007053698A2 (fr) 2007-05-10
ES2402666T3 (es) 2013-05-07
PL1951232T3 (pl) 2013-09-30
IES20060793A2 (en) 2007-05-30
DE202006014131U1 (de) 2007-01-04
NO20082460L (no) 2008-07-30
BE1017786A3 (de) 2009-07-07
BG1145U1 (bg) 2009-02-27
HK1106451A1 (en) 2008-03-14
EP1951232A4 (fr) 2009-03-11
NL1032774C1 (nl) 2007-05-02
FIU20060451U0 (fi) 2006-10-30
ES1064414U (es) 2007-03-16
AU2006308718C1 (en) 2015-10-08
US20090221621A1 (en) 2009-09-03
AU2006308718B2 (en) 2013-01-10
DK1951232T3 (da) 2013-05-06
FR2892634A3 (fr) 2007-05-04
KR101365031B1 (ko) 2014-02-21
DK200600272U4 (da) 2008-06-13
NO20064997L (no) 2007-05-02
HUP0600816A2 (en) 2008-05-28
DK200600272U1 (da) 2007-02-23
FI7512U1 (fi) 2007-05-25
PT1951232E (pt) 2013-05-13
PT103597A (pt) 2007-05-31
WO2007053698A3 (fr) 2007-06-28
EP1951232B1 (fr) 2013-04-03
AU2006308718A1 (en) 2007-05-10
KR20080064198A (ko) 2008-07-08
AU2006308718C8 (en) 2015-12-24
SI1951232T1 (sl) 2013-06-28
JP2009513717A (ja) 2009-04-02
EP1951232A2 (fr) 2008-08-06
CN103800300A (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
FR2892634B3 (fr) Procedes de reduction du dose dumping induit par l'alcool pour des formes posologiques orales d'opioides a liberation prolongee
EP1793809A4 (fr) Forme posologique d'ibuprofene a liberation modifiee
IL182964A0 (en) Gabapentin prodrug sustained release oral dosage forms
IL238308B (en) Pharmaceutical preparations containing azalastine
IL198869A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A PDGFRa ANTAGONIST
IL182255A0 (en) Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
IL194277A0 (en) Solid oral dosage form containing an enhancer
EP2040731A4 (fr) Forme posologique solide à administrer par voie orale contenant un activateur
PL1701698T3 (pl) Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779
EP1883406A4 (fr) Compositions et procedes pour la liberation prolongee de beta-alanine
IL178458A (en) Pharmacy kit for the use of oral contraceptives in a woman
ZA200708223B (en) Dispenser for releasing treatment composition into a toilet bowl
EP1648474A4 (fr) Methodes et compositions pharmaceutiques pour cicatriser des lesions
EP1701705A4 (fr) Absorption amelioree de formes de dosage a liberation modifiee
IL177402A0 (en) Composition for oral administration of tamsulosin hydrochloride
IL179992A0 (en) Immediate release formulations of memantine oral dosage forms
ZA200705012B (en) Oral solid dosage forms containing a low dose of estradiol
EP1846000A4 (fr) Compositions pharmaceutiques contenant du bisphosphonate, destinees a ameliorer l'absorption orale
EP1968609A4 (fr) Compositions pharmaceutiques et procedes pour l'utilisation de composes sulfhydryles hautement lipophiles
ZA200804734B (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
GB0616703D0 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
GB0612326D0 (en) Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
EP1937414A4 (fr) Forme pharmaceutique pour muqueuses orales
AP2004003087A0 (en) Oral dosage form for controlled drug release
HU0203985D0 (en) Use of a pharmaceutical composition for alleviating side effect of a disease